Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabazitaxel - Sanofi

Drug Profile

Cabazitaxel - Sanofi

Alternative Names: 116 258; Jevtana; RPR 116258; RPR 116258A; Taxoid-116258; TXD 258; XRP6258

Latest Information Update: 06 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer AIO Studien gGmbH; Bristol Haematology and Oncology Centre; European Organisation for Research and Treatment of Cancer; German Breast Group; Sanofi; SCRI Development Innovations; Sidney Kimmel Cancer Center; University Hospitals Bristol NHS Foundation Trust
  • Class Antineoplastics; Taxanes
  • Mechanism of Action Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Brain metastases; Breast cancer; Germ cell and embryonal neoplasms; Liposarcoma; Penile cancer; Small cell lung cancer; Urogenital cancer
  • Phase I/II Solid tumours
  • No development reported Gastric cancer; Head and neck cancer

Most Recent Events

  • 01 Jul 2018 University of Alabama at Birmingham, Astellas Pharma and Sanofi initiates enrolment in a phase I trial for Prostate Cancer (Metastatic disease, First line therapy, Combination therapy) in USA (NCT03110588)
  • 31 May 2018 Sanofi completes the phase III FIRSTANA trial in Prostrate cancer in Australia, Belarus, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Israel, Italy, Japan, Mexico, Peru, Poland, Portugal, Romania, Russia, Spain, Sweden, Taiwan, Turkey, Ukraine and USA (NCT01308567)
  • 10 May 2018 Sanofi completes the PRIMCAB phase-II trial in Prostate cancer (Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02379390)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top